Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

NCT05608213 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

187

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

PROCEDURE: Lenvatinib Plus I-125 Seed Brachytherapy
DRUG: Lenvatinib

Sponsor

Second Affiliated Hospital of Guangzhou Medical University